CompletedEarly Phase 1NCT03316274

Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma

Studying Kaposi sarcoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of California, San Francisco
Principal Investigator
Chia-ching Wang, MD
University of California, San Francisco
Intervention
Nivolumab(drug)
Enrollment
12 enrolled
Eligibility
18 years · All sexes
Timeline
2018 – 2021

Study locations (1)

Collaborators

Bristol-Myers Squibb · National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03316274 on ClinicalTrials.gov

Other trials for Kaposi sarcoma

Additional recruiting or active studies for the same condition.

See all trials for Kaposi sarcoma →

← Back to all trials